The Middle East Journal of Anesthesiology (MEJA) is an open-access journal that publishes original work in the fields of anesthesiology and pain medicine. This includes clinical or laboratory investigations. MEJA is published 3 times per year (October, February, and June).
Manuscripts may only be submitted electronically to the Journal's email address:
email@example.com. Receipt of manuscripts will be acknowledged by an e-mail to the corresponding author. Accepted manuscripts will appear on the journal website:
Authors should allow approximately 4-6 months for a decision. MEJA does not allow rejected manuscripts to be resubmitted.
Authors are responsible for avoiding plagiarism.
General Editorial, Legal and Ethical Issues
MEJA follows the ICMJE Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals. All authors must have made substantial contributions to the work submitted (e.g., participation in design, execution, analysis, and/or interpretation of the work, drafting or revising the manuscript, giving final approval of the version to be published, taking accountability for all aspects of the work. The list and order of authors must be established at the time of original submission. Any change to authorship after submission is not allowed. Manuscripts must be written by the authors; ghostwritten papers are unacceptable. All authors must complete the Copyright Transfer/Disclosure Form when requested.
Articles shall be received in English and will only be published in English.
Role of the Corresponding Author
Each manuscript must have a single Corresponding Author who is accountable for the research and reporting. He/She assumes primary responsibility for communication with MEJA during the manuscript submission, peer review and publication process, and ensures that all journal’s policies and administrative requirements, ethics committee approval, clinical trial registration, and the gathering conflict of interest forms, are properly completed. Upon submission, the Corresponding Author is required to attest to the validity and legitimacy of the data and interpretation, on behalf of all authors (who are also responsible for the validity and legitimacy of the data and interpretation). The Corresponding Author is responsible for ensuring that all authors meet the criteria for authorship, have reviewed and approved the manuscript and have completed the conflict of interest disclosures. The Corresponding Author must also be available after publication to respond to critiques of the work and to cooperate with any requests from the journal for data or additional information should questions about the manuscript arise after publication.
Conflicts of Interest
Each author must disclose all potential conflicts of interest based on the recommendations of the International Committee of Medical Journal Editors. Conflicts of interest and/or sponsorship/funding sources must appear on the title page. Authors must disclose commercial associations that might pose a conflict of interest in connection with the work submitted. Consultancies, equity interests, or patent licensing arrangements should also be noted at submission.
Each author must complete and submit the journal’s copyright transfer agreement prior to publishing of the manuscript.
Compliance with Funder-mandated Open Access Policies
At submission, please disclose any applicable funding sources that require open access publication.
Duplicate, Prior or Divided Publication
Submitted manuscripts must not have been published elsewhere, in whole or in part, on paper or electronically. This does not apply to abstracts of scientific meetings which should be disclosed on the title page.
Scientific misconduct include falsification of data, plagiarism, improper designations of authorship, duplicate publication, misappropriation of others' research, failure to disclose conflict(s) of interest, and failure to comply with applicable legislative or regulatory requirements. In general, MEJA follows the recommendations of the Committee on Publication Ethics (COPE) when working to address allegations of misconduct. Involved parties generally will be contacted to provide an explanation of the situation. As needed, MEJA may also contact the institution at which the study was conducted and any other involved journals. At the end of investigation, the Editor-in-Chief will respond with an appropriate action.
Human experimentation must conform to ethical standards and be approved by the appropriate Institutional Review Board (IRB). A statement concerning IRB approval and consent procedures must appear at the beginning of the Methods section. On occasion, the Editor-in-Chief may request a copy of the approved IRB application from the author.
Experimental work on animals must conform to the Guide for the Care and Use of Laboratory Animals, which is available from the National Academy of Science. Adherence to all relevant regulations and/or approval of the appropriate institutional Animal Care Committee or governmental licensure of the investigator and/or laboratory must be obtained. A statement concerning such approval must be included at the beginning of the Methods section.
Authors of preclinical trials (experiments in animals, cells, molecules, or other biological foci) should consult ARRIVE guidelines for transparent reporting. Authors should provide adequate description of the methods used, indicate measures for reducing bias (e.g., random allocation and blinding), describe how the sample size was determined, and highlight the data analysis plan.
MEJA welcomes papers based on well done surveys.
Authors of observational studies should consult the guidelines published by the STROBE group.
Authors should consult the guidelines published by the CONSORT group [Moher D, et al for the CONSORT Group: The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285:1987-91. Authors should consult the CONSORT checklist for items required when reporting a randomized clinical trial.
Registration of Clinical Trials: All clinical trials involving assignment of patients to treatment groups must be registered before patient enrollment, effective with trials beginning January 1, 2019. The registry, registration number, principal investigator's name, and registration date must be stated in the first paragraph of the Methods section of the manuscript. It must also be included on the title page of the manuscript.
Systematic reviews and meta-analyses
Authors should review the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements and guidelines.
The review process will take approximately 4-6 months. Upon receipt of a manuscript, it will be assigned to be evaluated by 2-3 reviewers expert in the field. Each of these items will be reviewed:
Abstract clearly and accurately states the study objectives/hypotheses and clearly describes data analysis and study findings
Study objectives and/or hypotheses clearly stated
Study design is appropriate for the stated aims
Primary and secondary outcomes clearly identified and defined
Statistical methods appropriate and clearly described
Missing data appropriately described and handled
Sample size justified
Results section follows clearly from the study objectives and statistical methods
Treatment effect estimates and their variability are reported
Confounding is carefully addressed for observational studies
Tables and Figures clear and self-explanatory
Limitations of design and statistical methods clearly described
Conclusions and Interpretations justified by the design and results
P-values appropriately reported
Editorial Decisions and Appeals Process
Decisions on manuscripts submitted to MEJA are final. Rejected manuscripts are not allowed to be resubmitted as new manuscripts. If an author wishes to appeal an editorial decision, the appeal must be based on strong evidence. Appeals should be provided by the corresponding author. Decision whether to consider or accept an appeal is made by the Editor-in-Chief.
Types of manuscripts to be considered for publication:
- Original Investigations
- Letters to the Editors/Correspondence
- Review Articles
- Case reports
All manuscripts should be submitted via the journal’s e-mail address (firstname.lastname@example.org). Manuscripts that do not satisfy minimum submission requirements will be returned to authors to correct. All submissions require a Title Page. Manuscripts must be double spaced with wide margins (1.5 inches or 3.8cm for all margins). Fonts should be 10 point or larger. Number pages consecutively at the upper right corners and numbers should start with the title page. Manuscripts may be submitted as single Word document files, including title page, references, figure legends, figures, and tables.